Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | CLO & Secretary | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,854 |
Ending reported balance
After 2026-10-02 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 340 · Balance 36,854 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. Row 2 · 2026-10-02 · Sale · Disposed 833 · Balance 36,021 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-02 · Sale · Disposed 1,976 · Balance 34,045 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-02 · Sale · Disposed 1,535 · Balance 32,510 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-02 · Sale · Disposed 404 · Balance 32,106 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-02 · Sale · Disposed 235 · Balance 31,871 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-02 · Sale · Disposed 17 · Balance 31,854 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.27 · Expires 2032-08-01 | Direct | 29,104 |
Reported balance
After 2026-10-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-02 · Exercise / conversion · Disposed 340 · Balance 29,104 F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2024 Filed Aug 31, 2024 00:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-24-000079 · edgardoc.xml · derivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,444 Underlying: Common Stock · 1,500 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| August 28, 2024 Filed Aug 31, 2024 00:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,500 | $106.39 | $159,590.55 |
DisclosureSEC source: 0002001011-24-000079 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,534 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $106.3200 to $106.4700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 28, 2024 Filed Aug 31, 2024 00:56 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,500 | $52.27 | $78,405.00 |
DisclosureSEC source: 0002001011-24-000079 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2024 Filed Jun 3, 2025 00:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 897 | $100.16 | $89,839.04 |
DisclosureSEC source: 0002001011-25-000037 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,637 F1 · kind: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 23:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 329 | $60.71 | $19,972.60 |
DisclosureSEC source: 0002001011-24-000065 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · Chief Legal Officer & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,534 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-24-000051 · edgardoc.xml · derivative · entry 3 Reardon Andrew · CIK 0001950232 · Chief Legal Officer & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,944 Underlying: Common Stock · 10,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 10,000 | $83.04 | $830,449.00 |
DisclosureSEC source: 0002001011-24-000051 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · Chief Legal Officer & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,205 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2024 Filed May 13, 2024 21:32 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 10,000 | $52.27 | $522,700.00 |
DisclosureSEC source: 0002001011-24-000051 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · Chief Legal Officer & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 29,272 | $0.00 Strike: $89.20 | $0.00 |
DisclosureSEC source: 0002001011-24-000030 · edgardoc.xml · derivative · entry 2 Reardon Andrew · CIK 0001950232 · CHIEF LEGAL OFFICER & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,272 Underlying: Common Stock · 29,272 shares Expires 2034-02-27 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,208 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000030 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CHIEF LEGAL OFFICER & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,205 F1 · shares: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 01:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 593 | $74.65 | $44,267.45 |
DisclosureSEC source: 0002001011-24-000019 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CHIEF LEGAL OFFICER & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,997 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| December 29, 2023 Filed Jan 4, 2024 21:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 179 | $60.71 | $10,866.55 |
DisclosureSEC source: 0002001011-24-000010 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CHIEF LEGAL OFFICER & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,590 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 897 | $68.73 | $61,650.81 |
DisclosureSEC source: 0000886163-23-000051 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CHIEF LEGAL OFFICER & 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,411 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 21:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 300 | $69.92 | $20,977.29 |
DisclosureSEC source: 0000899243-23-009799 · doc4.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,308 Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 15,393 | $0.00 Strike: $75.09 | $0.00 |
DisclosureSEC source: 0000899243-23-006296 · doc4.xml · derivative · entry 2 Reardon Andrew · CIK 0001950232 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,393 Underlying: Common Stock · 15,393 shares Expires 2033-02-23 F2 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from February 23, 2023, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after February 23, 2023 and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 5,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006296 · doc4.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,608 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on February 15, 2024; February 15, 2025; and February 15, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 02:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,073 | $72.90 | $78,221.70 |
DisclosureSEC source: 0000899243-22-037324 · doc4.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,940 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.